Sweden's Qlife Q1 revenue drops, losses widen slightly

Qlife Holding AB

13/05/2026 07:40

Overview

Sweden blood testing platform's Q1 revenue fell sharply, losses widened slightly

Company advanced strategic partnership talks and launched pharmacy pilot projects in Europe

Qlife completed rights issue, raising SEK 26 mln before set-offs and issue costs

Outlook

Qlife expects one or more strategic partnerships to materialize during 2026, subject to ongoing discussions

Company will continue developing the Egoo Health platform and evaluating commercial opportunities with potential partners

Qlife says timing of specific partnership agreements is uncertain despite encouraging engagement levels

Result Drivers

LIMITED REVENUE - Co said revenue remains limited due to focus on platform development, validation, and strategic partnership activities rather than immediate commercial expansion

COST CONTROL - Q1 characterized by continued discipline in cost control and capital allocation, per CEO

Company press release: ID:nWkr4JxKWX

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 21,000
Q1 Adjusted EPS
-SEK 0.73
Q1 EBITDA
-SEK 5.50 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)